Nothing Special   »   [go: up one dir, main page]

Daggett Jr et al., 1987 - Google Patents

The superiority of cold oxygenated dilute blood cardioplegia

Daggett Jr et al., 1987

View PDF
Document ID
892627041152129797
Author
Daggett Jr W
Randolph J
Jacobs M
O'Keefe D
Geffin G
Swinski L
Boggs B
Austen W
Publication year
Publication venue
The Annals of thoracic surgery

External Links

Snippet

It has been clearly shown, both in a laboratory model and in humans, that oxygenation of crystalloid cardioplegic solutions markedly enhances myocardial preservation. The addition of a small volume of red cells to a crystalloid perfusate improves capillary perfusion. Based …
Continue reading at www.annalsthoracicsurgery.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation; Extra-corporeal blood circuits
    • A61M1/3601—Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit
    • A61M1/3603—Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit in the same direction

Similar Documents

Publication Publication Date Title
Daggett Jr et al. The superiority of cold oxygenated dilute blood cardioplegia
Rosenkranz et al. Warm induction of cardioplegia with glutamate-enriched blood in coronary patients with cardiogenic shock who are dependent on inotropic drugs and intra-aortic balloon support: initial experience and operative strategy
Hayashida et al. The optimal cardioplegic temperature
Dietrich et al. Reduction of blood utilization during myocardial revascularization
Ko et al. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock
Clowes Jr Extracorporeal maintenance of circulation and respiration
Hammond et al. Retrograde coronary sinus perfusion: a method of myocardial protection in the dog during left coronary artery occlusion
Shin’oka et al. Effects of oncotic pressure and hematocrit on outcome after hypothermic circulatory arrest
Singh et al. Electrolyte versus blood cardioplegia: randomized clinical and myocardial ultrastructural study
Allen et al. Studies on prolonged acute regional ischemia: VI. Myocardial infarction with left ventricular power failure: A medical/surgical emergency requiring urgent revascularization with maximal protection of remote muscle
Christakis et al. Diltiazem cardioplegia: a balance of risk and benefit
Roberts et al. Clinical evaluation of the relative effectiveness of multidose crystalloid and cold blood potassium cardioplegia in coronary artery bypass graft surgery: a nonrandomized matched-pair analysis
Niinikoski et al. Oxygen transport to tissue under normovolemic moderate and extreme hemodilution during coronary bypass operation
Vaughn et al. Warm blood cardioplegia
Tchouta et al. Twenty-four-hour normothermic perfusion of isolated ex vivo hearts using plasma exchange
Robertson et al. Perioperative management of the multiorgan donor
Johnson et al. Prolonged (24-hour) normothermic ex vivo heart perfusion facilitated by perfusate hemofiltration
US5462524A (en) Methods for improving recovery of heart function from open heart surgery
Alam Advances in resuscitation strategies
Winkler et al. Perfusion techniques of profound hypothermia and circulatory arrest for pulmonary thromboendarterectomy
CN109789087B (en) Isotonic aqueous crystal solution
Whyte et al. Extracorporeal life support after heart or lung transplantation
Carrier et al. Does retrograde administration of blood cardioplegia improve myocardial protection during first operation for coronary artery bypass grafting?
Feola et al. Improved oxygenation of ischemic myocardium by hemodilution with stroma-free hemoglobin solution
Reynolds et al. Myocardial preservation related to magnesium content of hyperkalemic cardioplegic solutions at 8° C